Welcome to the international HTA database

Showing [24040 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Ontario Health	Bariatric surgery for people with class I obesity and poorly controlled type 2 diabetes
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2023	NIHR Health Technology Assessment programme	Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2023	Institute for Clinical and Economic Review (ICER)	Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value
2023	NIHR Health Technology Assessment programme	Techniques to increase lumbar puncture success in newborn babies: the NeoCLEAR RCT
2023	Ontario Health	Wire-free, nonradioactive localization techniques to guide surgical excision of nonpalpable breast cancer tumours
2023	Ontario Health	Placental growth factor (PlGF)-based biomarkers for risk prediction in people with suspected preeclampsia
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Image-guided spinal injections in the treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Robot-assisted rehabilitation for incomplete spinal cord injury]
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	SMA therapies: mid- to long-term follow-up of spinal muscular atrophy (SMA) patients treated for ≥24 months with nusinersen or onasemnogene abeparvovec and ≥12 months for patients treated with risdiplam or combination therapies
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Strategies for recruitment and programme adherence in group programmes for children, adolescents and adults with overweight and grade 1 obesity]
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Myopia control spectacle lenses for children and adolescents]
2023	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Registries in Austria and their utilisation for healthcare improvement]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Autologous fat grafting in osteoarthritis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	[Endovenous laser therapy for varicose veins in the lower extremities]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Multigene panel testing for tumors of known origin]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Edaravone in amyotrophic lateral sclerosis]
2023	NIHR Health Technology Assessment programme	Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023	Institute for Clinical and Economic Review (ICER)	Value assessment framework
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Flash glucose monitoring system in diabetes mellitus patients]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of coronary sinus narrowing device for the treatment of refractory angina]
2023	Institute for Clinical and Economic Review (ICER)	ICER-PHTI assessment framework for digital health technologies
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pembrolizumab in triple-negative breast cancer]
2023	Institute for Clinical and Economic Review (ICER)	White bagging, brown bagging, and site of service policies: best practices in addressing provider markup in the commercial insurance market
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency ablation of parathyroid glands]
2023	Institute for Clinical and Economic Review (ICER)	Applying the results of comparative effectiveness research to control drug costs: policy options for California
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Contraception: comparison of hormonal coils and copper coils]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Levonorgestrel-releasing intrauterine device as contraceptive method in women of childbearing age]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Support for the implementation of new ways of working at the Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale]
2023	Norwegian Institute of Public Health (NIPH)	177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Evaluation of the lung cancer screening program]
2023	Institute for Clinical and Economic Review (ICER)	Advancing health technology assessment methods that support health equity
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Intraoperative CT imaging system for navigational spine surgery]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cannabidiol in epilepsy. National versus international products comparison]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2023	Institute for Clinical and Economic Review (ICER)	Assessment of barriers to fair access
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Low-level light therapy for primary dysmenorrhea]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[CROS and BICROS hearing aids in unilateral and asymmetric bilateral hearing loss]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Efficacy and safety of Emotional Freedom Techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Effectiveness of communication strategies for patients who are non-vocal due to artificial airways
2023	Health Technology Wales (HTW)	Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[von Willebrand Factor collagen binding activity [high quality immunoassay]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Medial pivot prosthesis in primary total knee arthroplasty]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Autologous platelet rich fibrin therapy to promote wound healing]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Multiplex PCR for moderate to severe acute lower respiratory tract infections]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Concept for routine practice data collection acc. to the Law for More Safety in the Supply of Medicines (GSAV) – exagamglogene autotemcel (sickle cell disease)]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Early detection tools for emotional distress in adult people with cancer]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Seoul Cognitive Status Test]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Deep brain stimulation for dystonia refractory to medical treatment]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Spinal cord stimulation in refractory neuropathic pain in adults: evaluation of efficacy, effectiveness, safety, and efficiency in painful diabetic neuropathy and failed back surgery and complex regional pain syndromes]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Use of biomaterials in tympanoplasty for tympanic membrane repair]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, diagnostic validity, and clinical effectiveness of transcutaneous measurement of partial pressure of oxygen in the management of diabetic foot]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[FONAKIDs® multimodal approach in congenital or acquired apraxia of speech]
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC PC RCT
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of early intervention programs in psychosis for adolescents and young adults]
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Nivolumab plus ipilimumab in pleural mesothelioma]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]
2023	Andalusian Health Technology Assessment Area (AETSA)	[Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Blood test for the identification and location of different types of cancer]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023	NIHR Health Technology Assessment programme	Evaluation of the Healthy Start Voucher Scheme in UK: a natural experiment using the Growing Up in Scotland record linkage study and the Infant Feeding Survey
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD-L1]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Safety, efficacy, and economic evaluation of the implementation of an abdominal aortic aneurysm screening program]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[PCR type nucleic acid amplification tests in blood applied to rapid etiological diagnosis in suspected sepsis: assessment of its diagnostic and prognostic utility, safety, and economic and organizational implementation considerations]
2023	National Evidence-based Healthcare Collaborating Agency (NECA)	[Magnetic resonance imaging-guided transurethral ultrasound ablation of prostatic hyperplasia]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Remote monitoring of lung function through self-administered spirometry in patients with asthma, chronic obstructive pulmonary disease or cystic fibrosis: evaluation of safety, clinical efficacy and implementation aspects]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Peripheral electrical nerve stimulation (PENS) therapy as treatment for refractory chronic neuropathic pain in adults: evaluation of safety, efficacy, clinical effectiveness, and cost-effectiveness]
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	[Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for glutaric acidemia type 1 (GA1)]
2023	Health Technology Wales (HTW)	Solution-focused assessment tools for improving the treatment of people with psychosis and schizophrenia within secondary mental health services
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	[Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for for long-chain acyl-CoA dehydrogenase deficiency (LCHADD) and mitochondrial trifunctional protein deficiency (TFPD)]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Health technology assessment framework: adaptation for digital health technology assessment]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2023	NIHR Health and Social Care Delivery Program	Rapid evaluation of service innovations in health and social care: key considerations
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	NIHR Health Services and Delivery Research programme	A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023	NIHR Health Services and Delivery Research programme	What happens after an NHS Health Check? A survey and realist review
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023	NIHR Health Services and Delivery Research programme	Identifying models of care to improve outcomes for older people with urgent care needs: a mixed methods approach to develop a system dynamics model
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty and stenting in patients with carotid artery stenosis]
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Biomarkers in Alzheimer's disease
2023	Institute for Clinical Effectiveness and Health Policy (IECS)	[Lecanemab in Alzheimer’s Disease]